SUS will have virus vaccine that causes bronchiolitis: who can take?

Immunizant is the result of an agreement between the Butantan Institute and the Pharmaceutical Pfizer. According to Agência Brasil, the country will be able to produce the vaccine locally from 2026.

Vaccine has about 82% efficacy in preventing VSR hospitalizations in infants under six months. The expectation is to significantly reduce hospitalizations and deaths associated with the virus, and the priority in vaccination will be for municipalities with greater number of births and serious cases of bronchiolitis.

What is the respiratory sincial virus

Respiratory Sincient Virus is the main cause of bronchiolitis in children. The VSR accounts for up to 75% of cases of the disease in children under two years and about 40% of children’s pneumonia, according to the Ministry of Health.

VSR transmission occurs quickly and silently. The virus spreads through droplets expelled when coughing or sneezing and contact with contaminated surfaces. The entrance to the body happens through the mucous membranes of the eyes, nose and mouth.

VSR symptoms range from common cold to respiratory failure. The paintings can range from light, such as runny nose and cough, serious, as difficulty breathing and wheezing. In babies under six months, there is a higher risk of evolution for respiratory failure.